JPMorgan Chase & Co. Lowers Stock Position in Twist Bioscience Corporation $TWST

JPMorgan Chase & Co. cut its position in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 29.2% during the 3rd quarter, Holdings Channel reports. The firm owned 1,018,234 shares of the company’s stock after selling 420,892 shares during the quarter. JPMorgan Chase & Co.’s holdings in Twist Bioscience were worth $28,653,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Royal Bank of Canada lifted its position in shares of Twist Bioscience by 11.8% during the 1st quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock worth $1,585,000 after buying an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after acquiring an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after acquiring an additional 37,577 shares during the period. Intech Investment Management LLC boosted its position in Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after purchasing an additional 4,591 shares during the last quarter. Finally, AlphaQuest LLC grew its stake in Twist Bioscience by 23.0% in the 2nd quarter. AlphaQuest LLC now owns 7,454 shares of the company’s stock valued at $274,000 after purchasing an additional 1,393 shares during the period.

Analyst Ratings Changes

A number of research firms have recently commented on TWST. Stephens initiated coverage on Twist Bioscience in a research note on Monday, November 3rd. They set an “overweight” rating and a $41.00 target price on the stock. Barclays raised their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, February 3rd. Evercore raised their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.88.

Twist Bioscience Stock Down 3.7%

TWST opened at $46.92 on Friday. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $57.88. The company has a market cap of $2.88 billion, a PE ratio of -36.66 and a beta of 2.24. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. The company has a 50 day moving average of $42.25 and a 200 day moving average of $33.93.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. The business’s quarterly revenue was up 16.9% compared to the same quarter last year. On average, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the transaction, the chief financial officer directly owned 130,031 shares in the company, valued at approximately $6,501,550. This trade represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $49.93, for a total transaction of $249,650.00. Following the transaction, the insider directly owned 138,581 shares of the company’s stock, valued at approximately $6,919,349.33. This represents a 3.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,609 shares of company stock worth $1,665,151 over the last quarter. Insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.